Press Releases
U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma
If approved, daratumumab will offer a new option for double refractory, heavily pre-treated patients Janssen Research & Development, LLC (Janssen) announced today...
Press Releases
Your Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV Community Organizations
Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression Seeking and sharing...
Press Releases
Johnson & Johnson Announces BARDA Funding Award to Accelerate Ebola Vaccine Program
Johnson & Johnson (NYSE: JNJ) announced today that Crucell Holland B.V., one of its Janssen Pharmaceutical Companies, has been awarded $28.5 million from The Biomedical...
Press Releases
Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People with a Specific Type of Lung Cancer
Genentech will discuss results with the U.S. Food and Drug Administration (FDA) as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer. ...
Press Releases
U.S. FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of hemophilia A Ninth breakthrough therapy designation for Genentech’s portfolio of medicines ...
Press Releases
New Directions in Breast Conserving Surgery – An Interview with Pat Whitworth, MD and Frank Vicini, MD
Additionally, Frank Vicini, MD, Chief Academic Officer for Michigan Healthcare Professionals and 21st Century Oncology and Professor of Radiation Oncology, discusses data from a...
Press Releases
SABCS15: ONT-380 Phase I results support progression to Phase II in advanced HER2+ breast cancer
Phase I data regarding the experimental cancer agent ONT-380 were presented recently at the 2015 San Antonio Breast Cancer Symposium, indicating initial efficacy...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.